Five Prime Therapeutics, Inc. (NASDAQ:FPRX) – Leerink Swann dropped their Q3 2017 earnings per share (EPS) estimates for shares of Five Prime Therapeutics in a research report issued to clients and investors on Tuesday. Leerink Swann analyst M. Schmidt now anticipates that the biotechnology company will post earnings of ($1.34) per share for the quarter, down from their previous forecast of ($1.23). Leerink Swann also issued estimates for Five Prime Therapeutics’ Q4 2017 earnings at ($1.34) EPS, FY2017 earnings at ($5.42) EPS and FY2018 earnings at ($6.28) EPS.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by $0.43. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. During the same period in the previous year, the business posted ($0.49) EPS. Five Prime Therapeutics’s revenue was down 16.1% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Equities Analysts Reduce Earnings Estimates for Five Prime Therapeutics, Inc. (NASDAQ:FPRX)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/leerink-swann-equities-analysts-reduce-earnings-estimates-for-five-prime-therapeutics-inc-nasdaqfprx/1471814.html.

Other equities research analysts have also recently issued research reports about the stock. Jefferies Group LLC restated a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a report on Thursday, June 8th. BidaskClub cut shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Zacks Investment Research cut shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Finally, ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Five Prime Therapeutics currently has an average rating of “Hold” and a consensus target price of $60.80.

Five Prime Therapeutics (FPRX) opened at 26.62 on Friday. The company’s market cap is $743.90 million. The company has a 50-day moving average of $29.56 and a 200 day moving average of $34.86. Five Prime Therapeutics has a 12 month low of $26.21 and a 12 month high of $60.98.

A number of large investors have recently made changes to their positions in the company. Creative Planning boosted its stake in shares of Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares during the period. Legal & General Group Plc boosted its stake in shares of Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after buying an additional 287 shares during the period. Rhumbline Advisers boosted its stake in shares of Five Prime Therapeutics by 1.4% in the second quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock worth $1,032,000 after buying an additional 484 shares during the period. Trillium Asset Management LLC boosted its stake in shares of Five Prime Therapeutics by 1.5% in the second quarter. Trillium Asset Management LLC now owns 65,295 shares of the biotechnology company’s stock worth $1,966,000 after buying an additional 955 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Five Prime Therapeutics by 5.8% in the first quarter. Bank of America Corp DE now owns 18,558 shares of the biotechnology company’s stock worth $671,000 after buying an additional 1,025 shares during the period. Institutional investors and hedge funds own 85.10% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.